Filing Details

Accession Number:
0000899243-20-025361
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-16 18:11:34
Reporting Period:
2020-09-14
Accepted Time:
2020-09-16 18:11:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1701541 Black Diamond Therapeutics Inc. BDTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1637054 Brent Hatzis-Schoch C/O Black Diamond Therapeutics, Inc.
139 Main Street
Cambridge MA 02142
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-14 4,078 $3.20 7,078 No 4 M Direct
Common Stock Disposition 2020-09-14 2,685 $30.76 4,393 No 4 S Direct
Common Stock Disposition 2020-09-14 1,186 $31.42 3,207 No 4 S Direct
Common Stock Disposition 2020-09-14 207 $32.55 3,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-09-14 4,078 $0.00 4,078 $3.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
198,498 2029-06-11 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $31.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 to $32.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.